HR 4273 · introduced · significant

Over-the-Counter Monograph Drug User Fee Amendments

What this bill does

This bill extends the FDA's program to collect fees from over-the-counter drug manufacturers through 2030.
Over-the-counter drug makers and facilities that request changes to FDA drug safety rules are affected.
The bill adjusts fee amounts for fiscal years 2026-2030 and requires the FDA to announce fees 60 days in advance.

Generated by claude-haiku-4-5

Community Threads

Started by Cosponsor

01
How might increasing user fees on over-the-counter drug manufacturers affect consumer prices for common medications like cold remedies or pain relievers?
02
What evidence supports the FDA's need to collect these fees through 2030 rather than funding drug safety oversight through general appropriations?
03
Which over-the-counter drug manufacturers would face the largest financial burden under the adjusted fee structure, and how might that reshape the market?

Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.

Sponsor · R-OH-5

Robert E. Latta

Citizen cosponsors

In Congress

3/ 435

House Reps cosponsoring

Introduced 2025-09-17

Joining the bill

Legislative timeline

2025-09-17 · house · Calendars
Placed on the Union Calendar, Calendar No. 254.
2025-09-17 · house · Committee
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-300.
2025-09-17 · Committee
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-300.
2025-07-23 · house · Committee
Ordered to be Reported (Amended) by the Yeas and Nays: 51 - 0.
2025-07-23 · house · Committee
Committee Consideration and Mark-up Session Held
2025-07-02 · house · IntroReferral
Referred to the House Committee on Energy and Commerce.
2025-07-02 · IntroReferral
Introduced in House
2025-07-02 · IntroReferral
Introduced in House

Citizen comments

No comments yet — be the first.